DK95291D0 - Rekombinante dna-molekyler - Google Patents

Rekombinante dna-molekyler

Info

Publication number
DK95291D0
DK95291D0 DK91952A DK95291A DK95291D0 DK 95291 D0 DK95291 D0 DK 95291D0 DK 91952 A DK91952 A DK 91952A DK 95291 A DK95291 A DK 95291A DK 95291 D0 DK95291 D0 DK 95291D0
Authority
DK
Denmark
Prior art keywords
dna molecules
polypeptides
carrier protein
human
processes
Prior art date
Application number
DK91952A
Other languages
English (en)
Other versions
DK95291A (da
Inventor
Emerald Martin Spencer
Carol Talkingtonverser
Original Assignee
Biogrowth Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23115154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK95291(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogrowth Inc filed Critical Biogrowth Inc
Publication of DK95291D0 publication Critical patent/DK95291D0/da
Publication of DK95291A publication Critical patent/DK95291A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK095291A 1988-12-22 1991-05-21 Rekombinante dna-molekyler DK95291A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29025088A 1988-12-22 1988-12-22
PCT/US1989/005791 WO1990006950A1 (en) 1988-12-22 1989-12-21 Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides

Publications (2)

Publication Number Publication Date
DK95291D0 true DK95291D0 (da) 1991-05-21
DK95291A DK95291A (da) 1991-08-16

Family

ID=23115154

Family Applications (1)

Application Number Title Priority Date Filing Date
DK095291A DK95291A (da) 1988-12-22 1991-05-21 Rekombinante dna-molekyler

Country Status (14)

Country Link
EP (2) EP0375438A3 (da)
JP (2) JPH04503352A (da)
KR (1) KR910700261A (da)
AT (1) ATE155793T1 (da)
AU (1) AU4836890A (da)
CA (1) CA2006322C (da)
DE (1) DE68928203T2 (da)
DK (1) DK95291A (da)
ES (1) ES2107422T3 (da)
GR (1) GR3025094T3 (da)
HK (1) HK1000826A1 (da)
IL (1) IL92816A0 (da)
WO (1) WO1990006950A1 (da)
ZA (1) ZA899832B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
AU713275B2 (en) * 1994-07-20 1999-11-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DK1141015T3 (da) 1999-01-06 2010-01-25 Genentech Inc Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
CA2538342C (en) 2003-09-12 2013-01-08 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
EP1670822A2 (en) 2003-10-03 2006-06-21 Genentech, Inc. Igf binding proteins
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
CA2641310C (en) 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
JP2020533344A (ja) 2017-09-11 2020-11-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 慢性肺疾患を治療するための方法および組成物
CA3194764A1 (en) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
IL89661A (en) * 1988-03-17 1999-05-09 Novo Nordisk As Heparin binding proteins
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法

Also Published As

Publication number Publication date
EP0451194B1 (en) 1997-07-23
CA2006322C (en) 2000-08-01
CA2006322A1 (en) 1990-06-22
DE68928203T2 (de) 1998-01-15
AU4836890A (en) 1990-07-10
ATE155793T1 (de) 1997-08-15
JPH11236400A (ja) 1999-08-31
IL92816A0 (en) 1990-09-17
DK95291A (da) 1991-08-16
JPH04503352A (ja) 1992-06-18
ZA899832B (en) 1990-10-31
GR3025094T3 (en) 1998-01-30
EP0375438A2 (en) 1990-06-27
EP0451194A1 (en) 1991-10-16
EP0451194A4 (en) 1992-09-02
DE68928203D1 (de) 1997-09-04
HK1000826A1 (en) 1998-05-01
WO1990006950A1 (en) 1990-06-28
KR910700261A (ko) 1991-03-14
EP0375438A3 (en) 1992-03-25
ES2107422T3 (es) 1997-12-01

Similar Documents

Publication Publication Date Title
DK95291A (da) Rekombinante dna-molekyler
DK677688D0 (da) Humane somatomedinbaererproteinunderenheder og fremgangsmaade til fremstilling af saadanne
IL92257A0 (en) Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them
DE3783191D1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
FI102768B1 (fi) Hybridi-DNA-molekyyli ja menetelmä fibronektiiniä sitovan proteiinin valmistamiseksi
DE721983T1 (de) Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
WO1995021919A3 (en) Protein having tpo activity
FI103892B1 (fi) Rekombinantti-DNA-molekyyli, joka koodaa polypeptidiä/proteiinia, jolla on oleellisesti vaskulaaristen antikoaguloivien proteiinien biologiset ominaisuudet sekä niiden valmistus
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
FI921600A0 (fi) Bjoerkpollenallergen p14 foer diagnos och behandling av allergiska sjukdomar.
PT98804A (pt) Processo de preparacao de igfbp-4 ou um fragmento da mesma
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO1995008628A3 (en) Nucleic acids encoding merosin, merosin fragments and uses thereof
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
Spencer et al. Uses for antibodies which bind to human somatomedin carrier protein subunits
MX9504057A (es) Proteina que tiene actividad tpo.